152 related articles for article (PubMed ID: 25161997)
21. Association of T2285C polymorphism in PARP1 gene coding region with its expression, activity and NSCLC risk along with prognosis.
Wang Y; Xia XB; Tang HZ; Cai JR; Shi XK; Ji HX; Yan XN; Xu T
Mutagenesis; 2021 Aug; 36(4):281-293. PubMed ID: 34132814
[TBL] [Abstract][Full Text] [Related]
22. [Relationship of insulin-like growth factor receptor single nucleotide polymorphism (SNP) with platinum-based chemotherapy outcomes in advanced non-small cell lung cancer].
Chen Y; Shao H; Li H; Han L; Zhang X
Zhongguo Fei Ai Za Zhi; 2012 Feb; 15(2):65-71. PubMed ID: 22336232
[TBL] [Abstract][Full Text] [Related]
23. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
Cuffe S; Azad AK; Qiu X; Qiu X; Brhane Y; Kuang Q; Marsh S; Savas S; Chen Z; Cheng D; Leighl NB; Goss G; Laurie SA; Seymour L; Bradbury PA; Shepherd FA; Tsao MS; Chen BE; Xu W; Liu G
Cancer Epidemiol; 2016 Apr; 41():50-6. PubMed ID: 26816351
[TBL] [Abstract][Full Text] [Related]
24. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
[No Abstract] [Full Text] [Related]
25. RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC.
Wang X; Cui E; Zeng H; Hua F; Wang B; Mao W; Feng X
PLoS One; 2012; 7(10):e43734. PubMed ID: 23071492
[TBL] [Abstract][Full Text] [Related]
26. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.
Cui LH; Yu Z; Zhang TT; Shin MH; Kim HN; Choi JS
Pharmacogenomics; 2011 Jun; 12(6):797-808. PubMed ID: 21605004
[TBL] [Abstract][Full Text] [Related]
27. Notch 3 protein, not its gene polymorphism, is associated with the chemotherapy response and prognosis of advanced NSCLC patients.
Shi C; Qian J; Ma M; Zhang Y; Han B
Cell Physiol Biochem; 2014; 34(3):743-52. PubMed ID: 25171754
[TBL] [Abstract][Full Text] [Related]
28. [Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].
Zhang GW; Cheng RR; Zhang FR; Li P; Chu HY; Song XJ; Zhang GJ
Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(34):2682-2688. PubMed ID: 32921017
[No Abstract] [Full Text] [Related]
29. Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.
Li L; Wan C; Wen FQ
Genet Mol Res; 2014 May; 13(2):3772-86. PubMed ID: 24938464
[TBL] [Abstract][Full Text] [Related]
30. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
[TBL] [Abstract][Full Text] [Related]
31. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
Joerger M; Burgers SA; Baas P; Smit EF; Haitjema TJ; Bard MP; Doodeman VD; Smits PH; Vincent A; Huitema AD; Beijnen JH; Schellens JH
Cancer; 2012 May; 118(9):2466-75. PubMed ID: 22031394
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.
Zhao X; Zhang Z; Yuan Y; Yuan X
Tumour Biol; 2014 Aug; 35(8):8335-41. PubMed ID: 24859833
[TBL] [Abstract][Full Text] [Related]
33. Osteopontin, Bone Morphogenetic Protein-4, and Vitamin D Receptor Gene Polymorphisms in the Susceptibility and Clinical Severity of Spinal Tuberculosis.
Wang G; Xie L; Hu J; Lu H; Liu X; Cao Y; Liu B; Zhang Y; Shen X
Cell Physiol Biochem; 2017; 41(5):1881-1893. PubMed ID: 28376475
[TBL] [Abstract][Full Text] [Related]
34. The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum.
Xie FJ; Zhao P; Kou JY; Hong W; Fu L; Hu L; Hong D; Su D; Gao Y; Zhang YP
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1443-8. PubMed ID: 22371153
[TBL] [Abstract][Full Text] [Related]
35. Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy.
Li P; Liu HL; Zhang ZQ; Lv XD; Chang YX; Wang HJ; Ma J; Ma ZY; Qu XJ; Teng YE
J Thorac Dis; 2018 Mar; 10(3):1635-1647. PubMed ID: 29707316
[TBL] [Abstract][Full Text] [Related]
36. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.
Jiang YH; Xu XL; Ruan HH; Xu WZ; Li D; Feng JG; Han QB; Mao WM
Med Oncol; 2014 May; 31(5):959. PubMed ID: 24722796
[TBL] [Abstract][Full Text] [Related]
37. Influence of
Zhao M; Zhang J; Chen S; Wang Y; Tian Q
Cancer Manag Res; 2020; 12():6755-6766. PubMed ID: 32801904
[TBL] [Abstract][Full Text] [Related]
38. VEGF single nucleotide polymorphisms predict improved outcome in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Qi H; Zhang W; Wang Y; Ge M; Wang T; Zhang L; Zhong M; Shi X; Liang X; Zhan Q; Li Q
J Chemother; 2023 Feb; 35(1):53-62. PubMed ID: 35262460
[TBL] [Abstract][Full Text] [Related]
39. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
40. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Molina MÁ; Robles AI; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MÁ
Surg Oncol; 2017 Sep; 26(3):278-285. PubMed ID: 28807247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
